Xueqiong Cao

First-line nivolumab plus ipilimumab or chemotherapy <i>versus</i> chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis

Xueqiong Cao, Hongfu Cai, Na Li et al. · Therapeutic Advances in Medical Oncology · 2022 · 22 citations · Full text

Cost-effectiveness analysis of nivolumab plus ipilimumab <i>versus</i> chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

Liu Yang, Xueqiong Cao, Na Li et al. · Therapeutic Advances in Medical Oncology · 2022 · 17 citations · Full text

First-line nivolumab plus chemotherapy <i>versus</i> chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis

Xueqiong Cao, Mingming Zhang, Na Li et al. · Therapeutic Advances in Medical Oncology · 2023 · 16 citations · Full text